Individualized model predictive control for the artificial pancreas: In silico evaluation of closed-loop glucose control

Индивидуализированное предиктивное управление моделью для искусственной поджелудочной железы: имитационная оценка замкнутого управления уровнем глюкозы
Claudio Cobelli, Lalo Magni, Mirko Messori, Gian Paolo Incremona
2018-01-18

artificial pancreasclosed-loop glucose controlmodel predictive controlsubcutaneous insulin deliverytype 1 diabetes
Despite the continuous efforts devoted to AP development in the last decades, an artificial pancreas (AP) system is not yet available on the market. One of the major issues involves the inter-subject variability affecting type 1 diabetes (T1D) patients, which makes the definition of a single controller suitable for any patient practically impossible. Moreover, a state-of-the-art, noninvasive, and portable AP system is composed of subcutaneous hardware components, and the control algorithm must be properly designed to reside on a standalone device with limited battery life and computational power. These characteristics make the design of a safe and effective AP system even more challenging, due to the inherent delays affecting the subcutaneous insulin delivery route and the tradeoff between control performance and computational power expenditure. As a result of the model predictive control's (MPC's) ability to address inherent delays of the process under control, it is one of the most promising control approaches in the context of an AP. However, the achievable control performance is strictly related to the prediction capabilities of the model included in the controller, which, in general, can be highly nonlinear. The currently used MPC in clinical experiments relies on a linear average glucose-insulin model designed to represent the average dynamics of a subject with diabetes. This non-individualized MPC is not designed to cope with patient-specific dynamics but is designed to be non-computationally demanding and robust enough to result in a safe and effective control law.
1
Artificial pancreas development is hindered by substantial inter-subject variability, making a single controller suitable for all type 1 diabetes patients impractical.
2
Clinical MPC experiments commonly use a non-individualized linear average model designed for low computational demand, robustness, and generally safe control rather than patient-specific optimization.
3
MPC performance depends strongly on the glucose-insulin model’s predictive accuracy, which may require representing highly nonlinear and patient-specific dynamics.
4
Model predictive control is promising for artificial pancreas applications because it can explicitly address delays in insulin delivery.
5
Subcutaneous insulin delivery introduces inherent delays, while standalone hardware imposes battery and computational constraints that complicate safe, effective control.

artificial pancreas systems for type 1 diabetes with subcutaneous insulin delivery

individualized model predictive control performance for closed-loop glucose regulation under patient-specific dynamics, delivery delays, and computational constraints

Publication Details
Publication Date
2018-01-18
Journal
Publisher
ISSN
Cited by
115
Access Type
Author Information
Authors
Claudio Cobelli
Lalo Magni
Mirko Messori
Gian Paolo Incremona
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%